The optimized A3Bdel_MLPA assay was used to analyze two panels of gDNA samples, i.e., a panel of 31 samples from the HapMap project and a panel of 17 samples derived from women with breast and/or ovarian cancer with different APOBEC3B deletion genotypes that were previously determined with the use of the A3Bdel_PCR assay (Figure 1D and Supplementary Figure 1). This evidence concerns the gene APOBEC3B and ovarian cancer.